Modality
Degrader
MOA
KRASG12Di
Target
B7-H3
Pathway
Proteasome
SchizophreniaRSV
Development Pipeline
Preclinical
Jan 2017
→ Jun 2030
PreclinicalCurrent
NCT04411541
1,546 pts·RSV
2022-01→2027-10·Completed
NCT06208328
1,244 pts·Schizophrenia
2017-01→2030-06·Completed
2,790 total pts2 indications
Phase 1
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-10-241.6y awayInterim· RSV
2030-06-254.2y awayInterim· Schizophrenia
Trial Timeline
2017Q2Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
Preclinical
Complet…
Preclinical
Complet…
Catalysts
Interim
2027-10-24 · 1.6y away
RSV
Interim
2030-06-25 · 4.2y away
Schizophrenia
Completed|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04411541 | Preclinical | RSV | Completed | 1546 | LiverFat |
| NCT06208328 | Preclinical | Schizophrenia | Completed | 1244 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 |